Kerberos proximal solutions inc l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 11

Kerberos Proximal Solutions, Inc. PowerPoint PPT Presentation


  • 119 Views
  • Uploaded on
  • Presentation posted in: General

Kerberos Proximal Solutions, Inc. Tom Goff Fred Khosravi John MacMahon Carl Simpson. Mar 01. Dec 01. Jun 03. Dec 04. Timeline. 1999-2001 Idea Generation & Evaluation. Carotid Embolic Protection Medical Device Design class (precursor to BioDesign) Company formation

Download Presentation

Kerberos Proximal Solutions, Inc.

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Kerberos proximal solutions inc l.jpg

Kerberos Proximal Solutions, Inc.

Tom Goff

Fred Khosravi

John MacMahon

Carl Simpson


Timeline l.jpg

Mar 01

Dec 01

Jun 03

Dec 04

Timeline


1999 2001 idea generation evaluation l.jpg

1999-2001Idea Generation & Evaluation

Carotid Embolic Protection

  • Medical Device Design class (precursor to BioDesign)

  • Company formation

  • Technology evolution

    • “Engineering” approach

    • Competition / intellectual property

  • Clinical trial/regulatory hurdles


Audience response l.jpg

Audience Response

Critical Decision #1: What should the company do next?

  • Develop their own carotid stent for testing with the protection device

  • Sell the company to a carotid stent developer

  • Find a new application for the technology


2001 2002 indication reevaluation l.jpg

2001-2002Indication Reevaluation

Refocus on saphenous vein graft (SVG)

embolic protection

  • Venture funding

  • Further technology development

  • Human clinical study under IDE

  • Complexity of approach/workflow integration issues

  • Product sizing requirements


Audience response6 l.jpg

Audience Response

Critical Decision #2: What should the company do next?

  • Redesign the product for easier usage in SVGs

  • Sell the company’s assets

  • Find a new application for the technology


2003 2005 indication reevaluation l.jpg

2003-2005Indication Reevaluation

& Product Redesign

Refocus on acute myocardial infarction

(AMI)/thrombectomy

  • Boston Scientific investment

  • Product redesign

  • 510(k) approval for peripheral indication

  • Human clinical studies in AMI

  • AMI competitor failures & study design issues

  • Difficulty of AMI sales


Audience response8 l.jpg

Audience Response

Critical Decision #3: What should the company do next?

  • Keep the company focused on selling the product for AMIs

  • Establish a corporate partnership for help in positioning/selling the product for AMIs

  • Sell the company’s assets

  • Find a new application for the technology


2005 2006 indication reevaluation l.jpg

2005-2006Indication Reevaluation

Refocus on peripheral arterial disease (PAD)

  • PAD clinical study data not required

  • Rapidly expanding market opportunity/easier sale

  • Use in combination with stenting/angioplasty/ atherectomy

  • Revenue from AMI and PAD sales

  • Company acquired!


Evolution summary l.jpg

Mar 01

Dec 01

Jun 03

Dec 04

Evolution Summary

TechnologyProximal Embolic ProtectionRinspiration Thrombectomy


Summary lesson be nimble be quick l.jpg

Summary LessonBe Nimble, Be Quick !

Market and product configuration

should not be set in stone upfront

Need for constantly evaluate:

  • Intellectual property

  • Clinical study design requirements

  • Product design

  • Work flow integration

  • Clinical study results

  • Competition

  • Expanding market opportunities

    Need ability to refocus/evolve quickly


  • Login